While preclinical studies have long suggested that ketamine's antidepressant effects depend on AMPAR activity, this study provides the first direct evidence supporting this mechanism in humans. The ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

When patients undergo general anesthesia, doctors can choose among several drugs. Although each of these drugs acts on neurons in different ways, they all lead to the same result: a disruption of the ...

A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...

While standard medications fail around a third of patients struggling with depression, ketamine provides a fast-acting alternative that scientists can now finally visualize. A new study from Yokohama ...

This framework was applied to neural recordings from animals receiving one of the three anesthetics—propofol, ketamine, and dexmedetomidine.

Positron emission tomography (PET) images using the novel tracer [¹¹C]K-2 visualize cell-surface α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) density in the living human brain ...

We are witnessing a long-awaited transformation in depression care. After decades of incremental change, new therapeutic ...

A new paper published in Cell Reports, in which researchers work with primates, sheds some light on the question. Researchers ...